Pim kinase inhibitors and methods of their use

Details for Australian Patent Application No. 2012202993 (hide)

Owner Novartis AG

Inventors Burger, Matthew; Lindvall, Mika; Han, Wooseok; Lan, Jiong; Nishiguchi, Gisele; Shafer, Cynthia; Bellamacina, Cornelia; Huh, Kay; Atallah, Gordana; McBride, Christopher; Antonios-McCrea Jr., William; Zavorotinskaya, Tatiana; Walter, Annette; Garcia, Pablo

Agent Davies Collison Cave

Pub. Number AU-A-2012202993

Parent 2008221263

Filing date 22 May 2012

Wipo publication date 14 June 2012

International Classifications

C07D 213/78 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

A61K 31/44 (2006.01) - Non-condensed pyridines

A61P 35/00 (2006.01) Antineoplastic agents

C07D 239/28 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

7 June 2012 Complete Application Filed

14 June 2012 Application Open to Public Inspection

  Published as AU-A-2012202993

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012202994-Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels

2012202992-Starting device for a competitor in a sports competition